Jasper Therapeutics Initiates Strategic Alternatives Review
Jasper Therapeutics announced that, following an evaluation of current market conditions, its board of directors has decided to initiate a review of strategic alternatives. Strategic alternatives being evaluated include, among other options, a sale of assets, licensing of assets, collaborations, a sale of the company, a business combination, merger or other strategic transaction, or an orderly wind-down of operations. In connection with this strategic review, Jasper will continue to evaluate cost-saving measures to preserve cash, and plans to continue to maintain compliance with regulatory and financial reporting requirements.
